Navigation Links
ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
Date:7/29/2008

FREDERICK, Md., July 29 /PRNewswire/ -- ImQuest BioSciences announced today the successful acquisition of funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV. The two year Small Business Innovative Research (SBIR) grant provides funding for the continued development of the dual-acting pyrimidinedione molecules which effectively inhibit two critical steps in the HIV replication pathway important for a microbicide. The research to be performed will enable ImQuest scientist's to comparatively evaluate their most potent lead preventative agents and define the most potent microbicide candidate for advanced preclinical and clinical development.

ImQuest's Executive Vice President and Chief Scientific Officer, Dr. Robert W. Buckheit, Jr. is the Principal Investigator of the project and leads ImQuest's efforts to develop microbicide and therapeutic products for treatment and prevention of HIV infection. "Women now account for over 50% of the cases of individuals living with AIDS and the successful development of a microbicide is essential for providing them with an effective means to protect themselves from infection," explained Dr. Buckheit. "In the absence of an effective vaccine, topical microbicides represent the best means to prevent new HIV infections throughout the world."

As a component of the grant, ImQuest scientists will work in collaboration with Dr. Patrick Kiser of The University of Utah to develop an optimal formulated gel product which can be used by women to prevent the sexual transmission of HIV. ImQuest plans to file an IND to initiate human clinical microbicide trials with their lead microbicide candidate in 2009.

ImQuest Life Sciences, a privately held U.S. company located in Frederick, Maryland specializes in early stage drug development of novel compounds for the treatment of infectious disease and cancer. ImQuest BioSciences, also located in Frederick, Maryland, is a leading provider of anti-infective therapeutic and microbicide development services to the biotechnology and pharmaceutical industry.

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.

Executive Vice President and Chief Scientific Officer

ImQuest Life Sciences, Inc.

301-696-0274

rbuckheit@imquest.com


'/>"/>
SOURCE ImQuest BioSciences
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
2. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
3. Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL
4. First Cancer Diagnostic Test Based on Rosetta Genomics Proprietary MicroRNA Technology Receives Regulatory Approval
5. Cynosure Receives CE Mark for Smartlipo MPX(TM) Workstation
6. SyntheMed Receives Canadian Approval for REPEL-CV(R)
7. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
8. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
9. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
10. Pharmasset Receives Notice of Allowance
11. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take certain ... inventor from Austin, Texas, has identified a solution. , She developed a prototype for ... lighting. As such, it eliminates the need to turn on a light when taking ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
Breaking Medicine News(10 mins):